TG Therapeutics arrives at its June 11 earnings call having surged 18% on the week to $43.37 — yet the short position that bears rebuilt through late May is essentially unchanged, leaving a loaded confrontation between momentum buyers and a stubborn bear camp heading into tomorrow's print.
The positioning picture is one of an entrenched standoff. Short interest barely moved despite the rally — it remains at 19.2% of the free float, close to the 19.1% level documented in last week's note. Bears rebuilt aggressively heading into the print but have not blinked at the price spike. The borrow market gives them no reason to: availability has actually loosened over the week, now running at roughly 305% of short interest — well above the 52-week floor of 190% — and the cost to borrow is just 0.42%, barely changed across the past month. With ample supply and negligible carry cost, there is no mechanical pressure forcing covers. Options traders meanwhile are leaning bullish rather than defensive. The put/call ratio is near its lowest reading of the past year at 0.40, below its 20-day average of 0.42, reflecting call-heavy positioning into the event rather than demand for downside protection.
The Street retains a constructive tilt, though targets vary widely. The most recent action came from HC Wainwright, which lifted its target from $60 to $70 following the last earnings print in early May, reiterating that level again on May 27. JP Morgan carries an Overweight with a $46 target — now below the current price — while Goldman Sachs sits at Neutral with a $39 target, also below where the stock trades. The mean consensus target of $48 implies limited upside from current levels, framing TGTX as a stock that has largely caught up to Street expectations on price. The bull case centres on BRIUMVI's single-infusion convenience, real-world market share gains, and pipeline expansion into further autoimmune indications. Bears counter that elevated R&D spend — including subcutaneous formulation development — is pressuring near-term profitability, with EPS projected to decline further through the year. EV/EBITDA is running at roughly 17.5x, up over the past week, while the P/E of 20.4x has eased modestly over the past month. The ORTEX short score sits at 73.2 — elevated but having edged lower across the past week from a recent peak of 74.2, suggesting incremental improvement in the short-side outlook even as the absolute position remains large.
Earnings history adds relevant texture. The last print on May 6 produced a 19% single-day gain and a 18% five-day move. The prior event in May 2026 also saw a 6.6% one-day gain followed by a 27% five-day move. TGTX has consistently delivered sharp post-earnings moves to the upside in recent history — a pattern that helps explain the call-heavy options positioning and the stock's 6% single-session gain on Tuesday as traders anticipated another strong release. The most correlated peers had a mixed week: EXEL gained 9% and PTCT added 8%, broadly consistent with TGTX's move, while NAMS fell 4% and NTLA dropped nearly 2%, underscoring how company-specific catalysts are dominating over sector direction.
Tomorrow's report is therefore less about whether BRIUMVI is growing — the market appears to believe it is — and more about whether management's commentary on operating expense trajectory, the subcutaneous formulation timeline, and full-year guidance can justify holding a stock now trading above most Street targets, against a short base that has shown no inclination to move.
See the live data behind this article on ORTEX.
Open TGTX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
